Company: TAK
Filing Date: 2025-12-08
Form Type: 6-K
Source: 0001395064-25-000164
Chunk: 0

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-12-08
Form: 6-K
Chunk 0
---
#### FORM 6-K

#### U.S. SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### Report of Foreign Private Issuer

#### Pursuant to Rule 13a-16 or 15d-16 of

#### the Securities Exchange Act of 1934

#### For the month of December 2025

#### Commission File Number: 001-38757

### TAKEDA PHARMACEUTICAL COMPANY LIMITED
<div align='center'>(Translation of registrant’s name into English)</div>

#### 1-1, Nihonbashi-Honcho 2-Chome

#### Chuo-ku, Tokyo 103-8668

#### Japan
<div align='center'>(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form 40-F ☐</div>

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Information furnished on this form:

### EXHIBIT
| Exhibit 
 Number  |     |                                                                                                                                                     |
| 1       |     | Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing RusfertideDelivers Durable Response and Hematocrit Control in Polycythemia Vera |

### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| Date: December 8, 2025 |     | TAKEDA PHARMACEUTICAL COMPANY LIMITED 
 By:                                   |     | /s/ Norimasa Takeda                               |
|:-----------------------|:----|:--------------------------------------|:----|:--------------------------------------------------|
|                        |     |                                       |     | Norimasa Takeda                                   
 Chief Accounting Officer and Corporate Controller |

News Release

<div align='center'>Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide